1,024 material Form 8-K filings that 799 companies we cover made with the SEC in August 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
National HealthCare reported net operating revenues of $374.9 million for the quarter ended June 30, 2025, up 24.7% from $300.7 million a year earlier, driven by a 9.6% rise in same-facility revenues and the August 1, 2024 acquisition of White Oak Management. GAAP net income attributable to NHC fell to $23.7 million from $26.8 million, while adjusted net income rose 64.7% to $25.7 million, so shareholders see higher revenue and adjusted earnings alongside lower GAAP earnings.
Net operating revenues $374.9 million vs $300.7 million, up 24.7%; same-facility net operating revenues up 9.6%
GAAP net income attributable to NHC $23.7 million vs $26.8 million; GAAP diluted EPS $1.52 vs $1.73
Adjusted net income $25.7 million vs $15.6 million, up 64.7%; adjusted diluted EPS $1.65 vs $1.00
Dividends declared of $0.64 per common share for the quarter vs $0.61 a year earlier
Koppers reported second quarter 2025 sales of $504.8 million, down from $563.2 million a year earlier, and GAAP diluted EPS of $0.81 versus $1.25. The company cut its 2025 forecast, lowering its sales outlook to $1.9 billion to $2.0 billion from $2.0 billion to $2.2 billion and its adjusted EBITDA outlook to $250 million to $270 million, because it expects continued lower demand. Adjusted EPS rose to $1.48 from $1.36, but the lower sales and guidance cut weigh on the outlook for shareholders.
Q2 2025 net sales were $504.8 million, down 10.4% from $563.2 million; GAAP diluted EPS was $0.81 versus $1.25
Adjusted EPS was $1.48 versus $1.36 a year earlier; adjusted EBITDA was $77.1 million versus $77.5 million
2025 guidance revised: sales of $1.9 billion to $2.0 billion (previously $2.0 billion to $2.2 billion) and adjusted EBITDA of $250 million to $270 million
Adjusted EPS guidance is $4.00 to $4.60; operating cash flow projection of $150 million was maintained
AAM (NYSE: AXL) reported second-quarter 2025 sales of $1.54 billion, down from $1.63 billion a year earlier, while net income rose to $39.3 million from $18.2 million. The filing says the net income increase reflects a $46.3 million gain on its Business Combination Derivative, while Adjusted EBITDA fell to $202.2 million from $208.4 million, and the company raised the low end of several full-year 2025 targets.
Sales were $1.54 billion versus $1.63 billion a year earlier, which the company attributed to lower volume and mix.
Diluted EPS was $0.32 versus $0.15; Adjusted EPS was $0.21 versus $0.19. Adjusted EBITDA margin was 13.2% versus 12.8%.
Full-year 2025 targets: Adjusted EBITDA $695 million to $745 million (previously $665 million to $745 million); sales $5.75 billion to $5.95 billion (previously $5.65 billion to $5.95 billion).
CEO David C. Dauch said shareholders of both companies approved the combination with Dowlais.
Sotera Health reported second-quarter 2025 net revenues up 6.4% to $294 million and Adjusted EBITDA up 9.8% to $151 million, and raised its full-year 2025 outlook for revenue, Adjusted EBITDA and Adjusted EPS. GAAP net income was $8 million, or $0.03 per diluted share, slightly below $9 million a year earlier, and includes a pending settlement of about $34 million related to ethylene oxide claims against Sterigenics.
Q2 2025 net revenues rose 6.4% to $294 million; Adjusted EBITDA rose 9.8% to $151 million
Q2 2025 net income was $8 million, or $0.03 per diluted share, versus $9 million, or $0.03, in Q2 2024
Full-year 2025 Adjusted EPS outlook raised to $0.75 to $0.82 from $0.70 to $0.76
Six-month net loss of $5 million, or $0.02 per diluted share, includes settlements related to ethylene oxide claims
Alpha Metallurgical Resources reported a second-quarter 2025 net loss of $5.0 million, or $0.38 per diluted share, narrowing from a $33.9 million loss in the first quarter but down from a $58.9 million profit a year earlier. The company lowered its 2025 cost of coal sales guidance to $101 to $107 per ton, cut its SG&A guidance, and raised its idle operations expense guidance. It also plans to restart its share repurchase program on an opportunistic basis, having refrained from buybacks for about five quarters.
Q2 2025 net loss of $5.0 million ($0.38 per diluted share) versus a $33.9 million loss in Q1 2025 and net income of $58.9 million in Q2 2024
Adjusted EBITDA of $46.1 million, up from $5.7 million in Q1 2025 and down from $116.0 million in Q2 2024
2025 cost of coal sales guidance lowered to $101 to $107 per ton from $103 to $110; SG&A guidance cut to $48 million to $54 million
Total liquidity of $556.9 million as of June 30, 2025; remaining buyback authorization of approximately $400 million
Under Armour reported first quarter fiscal 2026 results for the quarter ended June 30, 2025. Revenue fell 4% to $1.1 billion, while GAAP net loss narrowed to $3 million from $305 million a year earlier, when results included a litigation reserve. The company expects second quarter revenue to decline 6% to 7% and a GAAP operating loss of up to $10 million, which matters to shareholders because it signals continued sales pressure and uncertainty from tariffs.
Revenue declined 4% to $1.1 billion; North America fell 5% to $670 million and footwear fell 14% to $266 million.
GAAP operating income was $3 million, compared with a loss of $300 million a year earlier; diluted loss per share was $0.01.
Second quarter outlook: revenue down 6% to 7%, GAAP operating loss of $10 million to breakeven, and diluted loss per share of $0.07 to $0.08.
Cash and cash equivalents totaled $911 million, including $400 million in senior notes raised in the quarter, to be used toward $600 million in notes due June 2026.
Sylvamo reported second quarter 2025 net income of $15 million ($0.37 per diluted share), down from $27 million in the first quarter and $83 million a year earlier, with net sales of $794 million and adjusted EBITDA of $82 million. The company said results were in line with its outlook and guided third quarter adjusted EBITDA to $145 million to $165 million, citing lower planned maintenance outage expenses and improved volumes. For shareholders, the quarter was weaker, but the company expects a stronger second half.
Q2 net sales were $794 million, versus $821 million in Q1 2025 and $933 million in Q2 2024.
Net income was $15 million ($0.37 per diluted share), versus $27 million in Q1 2025 and $83 million in Q2 2024.
Third quarter adjusted EBITDA outlook is $145 million to $165 million, with planned maintenance outage expenses projected to fall by $66 million and no outages planned in the quarter.
$42 million remains on the $150 million share repurchase authorization from September 2023, and the board declared a $0.45 per share third quarter dividend.
Wendy's reported second-quarter 2025 results for the quarter ended June 29, 2025. Revenue and global systemwide sales declined, while diluted earnings per share rose 7.4% to $0.29, helped by a lower share count. The company lowered its full-year 2025 adjusted EPS and adjusted EBITDA outlook, which matters to shareholders because it signals weaker expected profit for the year.
Total revenues were $560.9 million, down 1.7% from $570.7 million a year earlier; diluted EPS was $0.29, up 7.4% from $0.27.
Global systemwide sales were $3.7 billion, down 1.8%; U.S. same-restaurant sales fell 3.6%, while International systemwide sales grew 8.7%.
Full-year adjusted EPS outlook is now $0.82 to $0.89, down from $0.92 to $0.98; adjusted EBITDA outlook is now $505 million to $525 million, down from $530 million to $545 million.
The board declared a regular quarterly dividend of $0.14 per share, payable September 16, 2025, to holders of record as of September 2, 2025.
ANI Pharmaceuticals reported second-quarter 2025 net revenues of $211.4 million, up 53.1% from a year earlier, and GAAP net income available to common shareholders of $8.1 million, or $0.36 per diluted share, compared with a loss of $0.14 per share in the prior-year period. The company raised its full-year 2025 guidance for net revenues to $818 million to $843 million and adjusted non-GAAP diluted EPS to $6.98 to $7.35.
Q2 2025 net revenues were $211.4 million, up 53.1% year over year, or 37.0% on an organic basis excluding the Alimera acquisition.
Cortrophin Gel net revenues were $81.6 million, up 66.0% year over year.
GAAP diluted EPS was $0.36 versus a loss of $0.14 a year earlier; adjusted non-GAAP diluted EPS was $1.80 versus $1.02.
Full-year 2025 net revenue guidance was raised to $818 million to $843 million from $768 million to $793 million.
Essent Group reported second-quarter 2025 net income of $195.3 million, or $1.93 per diluted share, versus $203.6 million, or $1.91 per diluted share, a year earlier, while total revenues rose to $319.1 million from $312.9 million. The company also declared a $0.31 quarterly dividend and disclosed $387 million of share repurchases year to date through July 31, which matters to shareholders because it returns capital while net income declined year over year.
Net income was $195.3 million for the quarter ended June 30, 2025, down from $203.6 million a year earlier; diluted EPS was $1.93 versus $1.91.
Total revenues were $319.1 million, up from $312.9 million in the second quarter of 2024.
Year to date through July 31, 2025, Essent repurchased 6.8 million shares for $387 million; $260 million remains under the $500 million plan.
The Board declared a $0.31 quarterly dividend, payable September 10, 2025, to holders of record on August 29, 2025.
Atmus Filtration Technologies reported second-quarter 2025 net sales of $454 million, up 4.8% from $433 million a year earlier, and GAAP net income of $60 million, or $0.72 per diluted share, versus $0.67 a year earlier. The company raised its 2025 outlook, with adjusted earnings per share now expected at $2.40 to $2.60, although gross margin fell to 28.9% from 30.5%.
Net sales of $454 million, up 4.8% from $433 million, driven mainly by higher volume and pricing
Diluted EPS of $0.72 versus $0.67; adjusted EPS of $0.75 versus $0.71
2025 guidance raised: revenue of $1,685 million to $1,735 million and adjusted EPS of $2.40 to $2.60
Gross margin 28.9% versus 30.5%; $20 million of stock repurchased during the quarter
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.